Anika Therapeutics, Inc. — FY2016 Form 10-K Summary
Business context and reporting period
Anika is a global orthopedic medicines company focused on hyaluronic-acid-based products, including ORTHOVISC, MONOVISC, CINGAL and HYALOFAST. Its product groups are orthobiologics, dermal, surgical and legacy ophthalmic/veterinary products. This filing covers the fiscal year ended December 31, 2016; fourth-quarter results are also presented.
Orthobiologics generated 87% of product revenue. The company primarily uses distributors, with a developing direct-sales model intended for U.S. commercialization of CINGAL if FDA approval is obtained.
Key financial metrics
| Metric | FY2016 | FY2015 | Change |
|---|---|---|---|
| Product revenue | $102.9 million | $87.7 million | 17% increase |
| Licensing, milestone and contract revenue | $0.4 million | $5.3 million | 92% decrease |
| Total revenue | $103.4 million | $93.0 million | 11% increase |
| Product gross profit | $78.9 million | $66.6 million | 18% increase |
| Product gross margin | 77% | 76% | Up 1 percentage point |
| Income from operations | $50.6 million | $48.1 million | 5% increase |
| Net income | $32.5 million | $30.8 million | 6% increase |
| Diluted EPS | $2.15 | $2.01 | 7% increase |
| Cash flow from operations | $23.8 million | $39.1 million | Decrease |
| Cash, cash equivalents and investments | $124.8 million | $138.5 million | Decrease |
| Working capital | $161.6 million | $159.2 million | Increase |
Calculated margins were approximately 49% for operating income and 31% for net income in FY2016. Research and development expense increased 19% to $10.7 million, while selling, general and administrative expense increased 22% to $18.0 million. The filing does not identify material funded debt; reported long-term liabilities were $8.7 million, including deferred tax and other liabilities.
Fourth-quarter 2016 product revenue was $28.3 million, total revenue was $28.7 million and net income was $8.1 million, compared with fourth-quarter 2015 product revenue of $25.6 million, total revenue of $30.9 million and net income of $11.0 million. The year-over-year quarterly net-income decline primarily reflects the $5.0 million MONOVISC milestone recognized in fourth-quarter 2015.
Material changes versus the prior comparable period
- Product revenue growth was led by orthobiologics, particularly global MONOVISC sales and initial CINGAL sales following launches in Canada and the European Union.
- Orthobiologics revenue increased 22% to $89.7 million; dermal revenue increased 22% to $2.8 million.
- Surgical revenue declined 7% to $5.4 million, and Other revenue declined 21% to $5.1 million.
- Product gross margin improved to 77% because of a more favorable product mix and increased sales of higher-margin products.
- Operating expenses increased faster than revenue, reflecting higher clinical-trial spending, headcount and professional fees.
- Operating cash flow fell to $23.8 million, driven principally by timing-related decreases in accounts payable and income-tax payable and increased accounts receivable and inventory requirements.
- The company repurchased $25.0 million of common stock under an accelerated share repurchase program, receiving 0.5 million shares at an average price of $47.08.
- Capital expenditures were $14.0 million in 2016. Cumulative spending on the Bedford manufacturing expansion reached $21.6 million, with total project spending expected to be approximately $25 million.
Guidance, outlook, commentary and risks
Management expected orthobiologics revenue to increase in 2017, supported by MONOVISC growth, additional CINGAL international launches and the planned European introduction of ORTHOVISC-T. Dermal, surgical and Other revenue were also expected to increase modestly. Management expected research and development and selling, general and administrative expenses to rise in 2017.
For U.S. CINGAL approval, the company submitted an IND in late 2016 and planned to begin a second Phase III trial in the first quarter of 2017, with the first patient expected to be treated in the second quarter. CINGAL was assigned to the FDA's CDER, increasing the regulatory complexity relative to a device-only pathway. HYALOFAST clinical enrollment was ongoing, and an FDA-approved Phase III trial for the tennis-elbow treatment was planned for the second half of 2017.
- Customer concentration is substantial: Mitek accounted for 75% of product revenue, and the five largest customers accounted for 83% in 2016. Mitek represented 66% of year-end accounts receivable.
- The company was transferring HYAFF manufacturing from Italy to Bedford, creating potential supply-interruption and validation risks. The Italian subsidiary was also moving to a new Padova facility.
- Product approvals, clinical-trial outcomes, reimbursement, competition, intellectual-property protection and regulatory compliance remain significant risks.
- International sales represented 19% of product sales, exposing results to foreign-exchange, economic and geopolitical risks.
- The company had $28.4 million of disclosed operating-lease and purchase commitments, including $16.5 million of purchase commitments.
- The 2015 $0.7 million impairment of acquired Hemostatic Patch IPR&D did not recur in 2016; no 2016 goodwill or other IPR&D impairment was recorded.
- Management stated that available financial resources were adequate to support operations for at least twelve months from the financial-statement issuance date.
Most important facts for investors to verify
- Whether MONOVISC and CINGAL growth can offset the company's dependence on Mitek and other large distributors.
- The timing, cost, clinical results and FDA pathway for the additional CINGAL Phase III trial and any subsequent NDA submission.
- Progress and final cost of the Bedford manufacturing expansion and the transition of HYAFF production from Italy.
- Whether operating cash flow improves as receivables, inventory and tax-payment timing normalize.
- The effect of increased R&D, commercial infrastructure and SG&A spending on future operating margins.
- Potential changes in reimbursement, pricing pressure, regulatory requirements and competing HA-based products.
- The absence of dividends and the impact of future share repurchases, equity awards and possible financing needs on shareholder returns and dilution.